<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058990</url>
  </required_header>
  <id_info>
    <org_study_id>S2313</org_study_id>
    <nct_id>NCT04058990</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)</brief_title>
  <official_title>A 2:1 Randomized Trial Comparing the Agent Paclitaxel-Coated PTCA Balloon Catheter vs SeQuent Please Drug Eluting Balloon Catheter for the Treatment of a Small Vessel De Novo Native Coronary Artery Lesion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Trial Comparing the Agent Paclitaxel-Coated PTCA Balloon Catheter vs SeQuent&#xD;
      Please Drug Eluting Balloon Catheter for the Treatment of a Small Vessel De Novo Native&#xD;
      Coronary Artery Lesion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective is to evaluate the safety and effectiveness of the Agent ™&#xD;
      Paclitaxel-Coated PTCA Balloon Catheter for the treatment of Japanese subjects with a small&#xD;
      vessel de novo native atherosclerotic coronary artery lesion or in-stent restenosis (ISR) of&#xD;
      a previously treated lesion.&#xD;
&#xD;
      Primary endpoint: Target Lesion Failure (TLF) rate at 6 months post index-procedure. TLF is&#xD;
      defined as any ischemia driven revascularization of the target lesion (TLR), myocardial&#xD;
      infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>SV study: A prospective, multicenter, 2:1 randomized, controlled, single-blind, non-inferiority trial.150 subjects are expected to be enrolled to support a 2:1 randomization. (Investigational test device: Agent DCB, N=100 subjects or Control device: SeQuent Please DCB, N=50 subjects)&#xD;
ISR substudy: A prospective, multicenter, single-arm, open-label trial. 30 subjects are expected to be enrolled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF) rate</measure>
    <time_frame>6 months post index-procedure</time_frame>
    <description>TLF is defined as any ischemia driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Agent Paclitaxel-Coated PTCA Balloon Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (Agent Paclitaxel-Coated PTCA Balloon Catheter with paclitaxel 2.0 μg/mm²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SeQuent Please Drug Eluting Balloon Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of a Small Vessel De Novo Native Coronary Artery Lesion with a paclitaxel-coated balloon. (SeQuent Please Drug Eluting Balloon Catheter with paclitaxel 3.0 μg/mm²)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device: Paclitaxel-Coated PTCA Balloon Catheter</intervention_name>
    <description>Percutaneous Transluminal Coronary Angioplasty</description>
    <arm_group_label>Agent Paclitaxel-Coated PTCA Balloon Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel</intervention_name>
    <description>Percutaneous Transluminal Coronary Angioplasty</description>
    <arm_group_label>SeQuent Please Drug Eluting Balloon Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 20 years of age.&#xD;
&#xD;
          2. Subject understands the trial requirements and the treatment procedures and provides&#xD;
             written informed consent before any study-specific tests or procedures are performed.&#xD;
&#xD;
          3. Subject is eligible for percutaneous coronary intervention (PCI).&#xD;
&#xD;
          4. Subject has documented stable angina pectoris or unstable angina pectoris. If subject&#xD;
             has documented stable angina pectoris, one of the following criteria meet.&#xD;
&#xD;
               -  ≥90% diameter stenosis.&#xD;
&#xD;
               -  Stenosis that is considered a cause of stable effort angina (Only when it's&#xD;
                  without confirmation of significant stenosis).&#xD;
&#xD;
               -  Stenosis that is confirmed a cause of functional ischemia with any test.&#xD;
&#xD;
          5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG).&#xD;
&#xD;
          6. Subject is willing to comply with all protocol-required follow-up evaluation.&#xD;
&#xD;
          7. Patients undergoing first or second treatment for ISR lesions for the non-randomized&#xD;
             ISR substudy.&#xD;
&#xD;
          8. The target lesion meets all following criteria.&#xD;
&#xD;
               -  Target lesion length must measure (by visual estimate) ≤28 mm.&#xD;
&#xD;
               -  Target lesion must be a visually estimated reference vessel diameter (RVD)&#xD;
                  ≥2.00mm and &lt;3.00 mm (This applys for SV trial. For ISR substudy: RVD ≥2.00mm and&#xD;
                  ≤4.00 mm.).&#xD;
&#xD;
               -  Target lesion must be a de novo lesion located in a native coronary artery with&#xD;
                  visually estimated stenosis ≥75% and &lt;100% (This applys for SV trial. For ISR&#xD;
                  substudy: Target lesion for ISR must be in-stent restenosis of a&#xD;
                  previously-treated lesion located in a native coronary artery with visually&#xD;
                  estimated stenosis ≥75% and &lt;100%.).&#xD;
&#xD;
               -  Coronary anatomy is likely to allow delivery of an investigational device to the&#xD;
                  lesions.&#xD;
&#xD;
               -  Target lesion must be successfully pre-dilated.&#xD;
&#xD;
          9. Planned treatment of 2 coronary artery lesions in 2 vessels may be treated (For SV&#xD;
             trial, up to two lesions per vessel can be treated. For ISR substudy, single lesion&#xD;
             per vessel can be treated.).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has had an acute myocardial infarction within 72 hours prior to the index&#xD;
             procedure.&#xD;
&#xD;
          2. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or&#xD;
             mechanical circulatory support, intractable ventricular arrhythmia, or ongoing&#xD;
             intractable angina.&#xD;
&#xD;
          3. Subject has severe left ventricular dysfunction with ejection fraction &lt;30%.&#xD;
&#xD;
          4. Subject has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant.&#xD;
&#xD;
          5. Subject is receiving or scheduled to receive chemotherapy within 30 days before or&#xD;
             after the index procedure.&#xD;
&#xD;
          6. Subject has renal failure with a serum creatinine of &gt; 2.0mg/dL or who is receiving&#xD;
             dialysis or chronic immunosuppressant therapy.&#xD;
&#xD;
          7. Subjects has one of the following.&#xD;
&#xD;
               -  Not expected to live for the duration of the study (1 year) by investigator's&#xD;
                  discretion due to other serious medical illness.&#xD;
&#xD;
               -  Current problems with substance abuse.&#xD;
&#xD;
               -  Planned procedure that may cause non-compliance with the protocol or confound&#xD;
                  data interpretation.&#xD;
&#xD;
          8. Planned PCI (including staged procedures) or CABG after the index procedure.&#xD;
&#xD;
          9. Subject previously treated at any time with intravascular brachytherapy.&#xD;
&#xD;
         10. Subject has a known allergy to contrast and/or the investigational device or&#xD;
             protocol-required concomitant medications, iopromide, raw materials of Agent DCB and&#xD;
             SeQuent Please DCB, P2Y12 inhibitor or aspirin).&#xD;
&#xD;
         11. Subject has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3.&#xD;
&#xD;
         12. Subject has a white blood cell (WBC) count &lt; 3,000 cells/mm3.&#xD;
&#xD;
         13. Subject has documented or suspected liver disease, including laboratory evidence of&#xD;
             hepatitis.&#xD;
&#xD;
         14. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions.&#xD;
&#xD;
         15. Subject has had a history of cerebrovascular accident (CVA) or transient ischemic&#xD;
             attack (TIA) within the past 6 months.&#xD;
&#xD;
         16. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding.&#xD;
&#xD;
         17. Target vessel has been treated with Paclitaxel Eluting Stent or Balloon prior to the&#xD;
             index procedure.&#xD;
&#xD;
         18. Target vessel has been treated with any type of PCI within 6 months prior to the index&#xD;
             procedure.&#xD;
&#xD;
         19. Target vessel requires the use of adjunctive primary treatment modalities immediately&#xD;
             prior to investigational device's treatment.&#xD;
&#xD;
         20. Non-target vessel has been treated with any type of PCI within 24 hours prior to the&#xD;
             index procedure.&#xD;
&#xD;
         21. Subject is participating in another investigational drug or device clinical trial that&#xD;
             has not reached its primary endpoint.&#xD;
&#xD;
         22. Subject intends to participate in another investigational drug or device clinical&#xD;
             trial within 6 months after the index procedure.&#xD;
&#xD;
         23. Subject with known intention to procreate within 6 months after the index procedure.&#xD;
&#xD;
         24. Subject is a woman who is pregnant or nursing.&#xD;
&#xD;
         25. Target lesion meets any of the following criteria:&#xD;
&#xD;
               -  Left main location.&#xD;
&#xD;
               -  Located within 5 mm of the origin of the left anterior descending (LAD) coronary&#xD;
                  artery or left circumflex (LCX) coronary artery by visual estimate.&#xD;
&#xD;
               -  &gt; 50% stenosis of an additional lesion proximal or distal to the target lesion&#xD;
                  (by visual estimate).&#xD;
&#xD;
               -  Located within a saphenous vein graft or an arterial graft.&#xD;
&#xD;
               -  Will be accessed via a saphenous vein graft or an arterial graft.&#xD;
&#xD;
               -  Involves a complex bifurcation (e.g., bifurcations requiring treatment with more&#xD;
                  than 1 stent).&#xD;
&#xD;
               -  TIMI flow 0 (total occlusion) prior to wire crossing.&#xD;
&#xD;
               -  Excessive tortuosity proximal to or within the lesion.&#xD;
&#xD;
               -  Extreme angulation proximal to or within the lesion.&#xD;
&#xD;
               -  Target lesion and/or target vessel proximal to the lesion is severely calcified&#xD;
                  by visual estimate to expect sub-optimal balloon expansion.&#xD;
&#xD;
               -  Target lesion and/or target vessel adjacent to the target lesion presents with&#xD;
                  dissection or aneurysm by visual estimate.&#xD;
&#xD;
               -  Restenosis from previous intervention (This is applicable only to SV trial.).&#xD;
&#xD;
               -  PCI within 10 mm proximal or distal to the target lesion (by visual estimate) at&#xD;
                  any time prior to the index procedure （This is applicable only to SV trial.）.&#xD;
&#xD;
               -  Planned treatment of a single lesion with more than 1 investigational device.&#xD;
&#xD;
               -  In-stent restenosis due to stent fracture or recoil (This is applicable only to&#xD;
                  ISR substudy.).&#xD;
&#xD;
         26. Non-target lesion to be treated during the index procedure meets any of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Located in the target vessel (This is applicable only to ISR substudy.).&#xD;
&#xD;
               -  Located within a bypass graft (venous or arterial).&#xD;
&#xD;
               -  Left main location.&#xD;
&#xD;
               -  Chronic total occlusion.&#xD;
&#xD;
               -  Involves a complex bifurcation.&#xD;
&#xD;
               -  Located within 15 mm of the proximal or distal shoulder of the target lesion by&#xD;
                  visual estimate in the case of the same vessel with a target lesion for SV trial.&#xD;
&#xD;
         27. Subject has unprotected left main coronary artery disease (&gt;50% diameter stenosis).&#xD;
&#xD;
         28. Thrombus, or possible thrombus, present in the target vessel.&#xD;
&#xD;
         29. Subject with known coronary artery spasm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masato Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Labour Health and Welfare Organization Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Ofuna</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama-City Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Saiseikai Nakatsu Hospital</name>
      <address>
        <city>Kita</city>
        <state>Osaka</state>
        <zip>530-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa-Ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The confidentiality of records/data obtained in the trial will remain anonymous for analysis and publication.&#xD;
The information and data, obtained from the trial is used without personal identification.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

